Last reviewed · How we verify
morphine mouthwash
morphine mouthwash is a Opioid analgesic Small molecule drug developed by Danish University of Pharmaceutical Sciences. It is currently FDA-approved for Oral pain and mucositis (particularly in cancer patients undergoing chemotherapy or radiotherapy), Painful oral ulcers and lesions.
Morphine mouthwash delivers the opioid analgesic morphine topically to oral mucosa to relieve oral pain and discomfort.
Morphine mouthwash delivers the opioid analgesic morphine topically to oral mucosa to relieve oral pain and discomfort. Used for Oral pain and mucositis (particularly in cancer patients undergoing chemotherapy or radiotherapy), Painful oral ulcers and lesions.
At a glance
| Generic name | morphine mouthwash |
|---|---|
| Sponsor | Danish University of Pharmaceutical Sciences |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Morphine is a mu-opioid receptor agonist that binds to opioid receptors in the oral cavity and potentially in systemic circulation following mucosal absorption. When applied as a mouthwash, it provides local analgesia for painful oral conditions while allowing some systemic absorption for broader pain relief. This formulation is particularly useful for patients with oral mucositis, ulcers, or other painful oral lesions who may have difficulty swallowing conventional oral medications.
Approved indications
- Oral pain and mucositis (particularly in cancer patients undergoing chemotherapy or radiotherapy)
- Painful oral ulcers and lesions
Common side effects
- Local irritation or burning sensation
- Systemic opioid effects (drowsiness, dizziness)
- Nausea
- Constipation
Key clinical trials
- Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients. (PHASE1, PHASE2)
- Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy (PHASE4)
- Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer (PHASE2, PHASE3)
- Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- morphine mouthwash CI brief — competitive landscape report
- morphine mouthwash updates RSS · CI watch RSS
- Danish University of Pharmaceutical Sciences portfolio CI
Frequently asked questions about morphine mouthwash
What is morphine mouthwash?
How does morphine mouthwash work?
What is morphine mouthwash used for?
Who makes morphine mouthwash?
What drug class is morphine mouthwash in?
What development phase is morphine mouthwash in?
What are the side effects of morphine mouthwash?
What does morphine mouthwash target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Danish University of Pharmaceutical Sciences — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Oral pain and mucositis (particularly in cancer patients undergoing chemotherapy or radiotherapy)
- Indication: Drugs for Painful oral ulcers and lesions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing